acyclovir triphosphate

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 咪唑并嘧啶类
• 英文名称: acyclovir triphosphate
• 英文别名: 2-amino-9-(2-hydroxyethoxymethyl)-1H-purin-6-one;phosphoric acid
• 化学式: C₈H₁₁N₅O₃*3H₃O₄P
• 分子量: 519.193
• InChiKey: ATIOWXMQGDQQEV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -2.26
• 重原子数：
  21
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  193
• 氢给体数：
  6
• 氢受体数：
  9

反应信息

• 作为产物：
  描述：

  阿昔洛韦 在 盐酸 、 磷酸三乙酯 、 potassium chloride 、 N,N-二异丙基乙胺 、 三氯氧磷 作用下， 以 1,4-二氧六环 、 水 为溶剂， 反应 6.08h， 生成 acyclovir triphosphate
  参考文献：
  名称：

  Phosphoramidate derivatives of acyclovir: Synthesis and antiviral activity in HIV-1 and HSV-1 models in vitro

  摘要：

  The antiviral activity against HIV and HSV and the chemical stability of ACV phosphoramidate derivatives were studied. The phosphoramidates of ACV demonstrated moderate activity. The best compound appeared to be 9-(2-hydroxymethyl)guanine phosphoromonomorpholidate (7), which inhibited virus replication in pseudo-HIV-1 particles by 50% at 50 mu M. It also inhibited replication of wild-type HSV-1 (9.7 mu M) as well as an acyclovir-resistant strain (25 mu M). None of the synthesised compounds showed any cytotoxicity. (C) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2012.08.008

文献信息

• COMPOSITIONS AND METHODS FOR TREATMENT OF VIRAL DISEASES
  申请人：Johansen Lisa M.

  公开号：US20100009970A1

  公开（公告）日：2010-01-14

  The present invention features compositions, methods, and kits useful in the treatment of viral diseases. In certain embodiments, the viral disease is caused by a single stranded RNA virus, a flaviviridae virus, or a hepatic virus. In particular embodiments, the viral disease is viral hepatitis (e.g., hepatitis A, hepatitis B, hepatitis C, hepatitis D, hepatitis E) and the agent or combination of agents includes sertraline, a sertraline analog, UK-416244, or a UK-416244 analog. Also featured are screening methods for identification of novel compounds that may be used to treat a viral disease.

  本发明涉及用于治疗病毒性疾病的组合物、方法和试剂盒。在某些实施方式中，病毒性疾病是由单链RNA病毒、黄病毒科病毒或肝病毒引起的。在特定实施方式中，病毒性疾病是病毒性肝炎（例如甲型肝炎、乙型肝炎、丙型肝炎、丁型肝炎、戊型肝炎），药剂或药剂组合包括舍曲林、舍曲林类似物、UK-416244或UK-416244类似物。还包括用于鉴定可用于治疗病毒性疾病的新化合物的筛选方法。
• Polymeric metformin and its use as a therapeutic agent and as a delivery vehicle
  申请人：The University of North Carolina at Chapel Hill

  公开号：US10426745B2

  公开（公告）日：2019-10-01

  Provided herein are polymers comprising Metformin residues (“PolyMet”) as useful therapeutic agents, delivery vehicles and transfection agents for nucleotides. Also provided herein are methods for the treatment of a disease or an unwanted condition in a subject, wherein the methods comprise administering PolyMet as a therapeutic agent to combat the disease or condition. Also provided herein are methods for the treatment of a disease or an unwanted condition in a subject, wherein the methods comprise administering a therapeutic agent in a delivery vehicle that comprises PolyMet. Further provided herein are methods for making PolyMet.

  本文提供了包含二甲双胍残留物（“PolyMet”）的聚合物，作为有用的治疗剂、传递载体和转染剂，用于核苷酸。本文还提供了一种治疗主体的方法，用于治疗受试者的疾病或不良状况，其中方法包括将PolyMet作为治疗剂施用以对抗疾病或状况。本文还提供了一种治疗受试者疾病或不良状况的方法，其中方法包括将治疗剂施用于包含PolyMet的传递载体中。本文还提供了一种制备PolyMet的方法。
• EGFR inhibitor and antiviral agent for simultaneous, separate or sequential use in the treatment and/or prevention and/or palliation of cancer
  申请人：Institut Gustave Roussy (IGR)

  公开号：EP2371369A1

  公开（公告）日：2011-10-05

  The application relates to a combination of biologically active compounds comprising at least one antiviral agent and at least one EGFR antagonist, for simultaneous, separate or sequential use in the treatment and/or prevention and/or palliation of malignant or pre-malignant neoplasms, preferably of solid malignant or pre-malignant neoplasms.

  该申请涉及一种生物活性化合物的组合，其中包括至少一种抗病毒剂和至少一种EGFR拮抗剂，用于同时、分开或顺序使用，用于治疗和/或预防和/或缓解恶性或癌前病变，最好是固体恶性或癌前病变。
• [EN] DELIVERY SYSTEM COMPLEXES COMPRISING A PRECIPITATE OF AN ACTIVE AGENT AND METHODS OF USE<br/>[FR] COMPLEXES DE SYSTÈME D'ADMINISTRATION COMPRENANT UN PRÉCIPITÉ D'UN AGENT ACTIF ET PROCÉDÉS D'UTILISATION
  申请人：UNIV NORTH CAROLINA CHAPEL HILL

  公开号：WO2021072407A1

  公开（公告）日：2021-04-15

  Provided herein are methods and compositions for the delivery of a combination of oxiplatin and folinic acid to a cell, tissue, or physiological site. The compositions comprise delivery system complexes comprising liposomes encapsulating dihydrate(1,2-diaminocyclohexane)platinum(II)-folinic acid or delivery system complexes comprising a 5-fluorouracil active metabolite. Also provided herein are methods for the treatment of cancer, wherein the methods comprise administering the delivery system complexes comprising dihydrate(1,2-diaminocyclohexane)platinum(II)-folinic acid or delivery system complexes comprising a 5-fluorouracil active metabolite that have therapeutic activity against the cancer.

  本文提供了一种将奥沙利铂和叶酸酯组合物传递到细胞、组织或生理部位的方法和组合物。该组合物包括传递系统复合物，其中包括脂质体封装的二水合物（1,2-二氨基环己烷）铂（II）-叶酸酯或包括5-氟尿嘧啶活性代谢物的传递系统复合物。本文还提供了一种治疗癌症的方法，该方法包括给予具有治疗活性的二水合物（1,2-二氨基环己烷）铂（II）-叶酸酯或包括5-氟尿嘧啶活性代谢物的传递系统复合物。
• Nano-structured compositions and methods of making and using the same
  申请人：Lee Robert

  公开号：US20070264349A1

  公开（公告）日：2007-11-15

  The present invention provides a new tri-phasic method for making nanoparticles of poorly soluble active pharmaceutical ingredients.

  本发明提供了一种新的三相法制备难溶性活性药物成分的纳米颗粒。